Core Viewpoint - ZIVO Bioscience, Inc. has decided to deregister its securities with the SEC and cease public reporting, believing this is in the best interests of shareholders at this stage of development [2][3]. Financial Considerations - The costs associated with maintaining a public listing, including SEC compliance, legal, financial reporting, and investor relations, are significant and consume a disproportionate share of resources for a company of ZIVO's size [3]. - Ongoing capital raises to fund public reporting expenses have led to shareholder dilution, reducing the ownership percentage of existing shareholders [4]. Revenue Potential - ZIVO anticipates meaningful revenue from its AgTech product line in the coming months due to established distribution relationships and advancing commercial activity [4]. - As a non-reporting company, ZIVO expects to retain and accumulate revenue and cash for the direct benefit of the company, potentially resulting in positive cash flow for the first time in its history [5]. Business Updates - The Animal Health division is progressing, with major global companies conducting due diligence on ZIVO's non-antibiotic immune-modulating technology, with formal partnership discussions anticipated [6]. - The University of Georgia has received funding to use ZIVO's product in studies addressing Avian Influenza, a significant issue for the poultry industry [7]. - In the AgTech and Human Nutrition segment, ZIVO LIFE™ microalgae ingredient has generated global commercial interest, and production capacity is being increased in anticipation of growing demand [8]. Commitment to Shareholders - The Board of Directors has eliminated board compensation and any investments by board members are made at full market price, demonstrating alignment with shareholder interests [9]. - The decision to cease public reporting is framed as a commitment to a better structure for building value, with shareholder interests at the center of decision-making [10].

Core Insights - ZIVO Bioscience, Inc. is a biotech and agtech R&D company focused on developing therapeutic and nutritional products from proprietary algal cultures [1] Company Progress - The company has made significant progress in its operations and is optimistic about its future direction [1]